Viamet’s ‘Valley fever’ drug candidate receives QIDP designation

Viamet Pharmaceuticals announced on Thursday that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to VT-1598, a novel candidate for the oral treatment of coccidioidomycosis, or Valley Fever. Valley Fever is an invasive fungal infection found primarily in the southwest United States that affects an estimated 150,000 people ["]